134 related articles for article (PubMed ID: 24628790)
1. Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?
Mottet N; Clarke N; De Santis M; Zattoni F; Morote J; Joniau S
BJU Int; 2015 Mar; 115(3):364-72. PubMed ID: 24628790
[TBL] [Abstract][Full Text] [Related]
2. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
Bahl A; Masson S; Birtle A; Chowdhury S; de Bono J
Cancer Treat Rev; 2014 Feb; 40(1):170-7. PubMed ID: 23958310
[TBL] [Abstract][Full Text] [Related]
3. Management of castrate-resistant prostate cancer in older men.
Ged Y; Horgan AM
J Geriatr Oncol; 2016 Mar; 7(2):57-63. PubMed ID: 26907565
[TBL] [Abstract][Full Text] [Related]
4. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
Fitzpatrick JM; Bellmunt J; Fizazi K; Heidenreich A; Sternberg CN; Tombal B; Alcaraz A; Bahl A; Bracarda S; Di Lorenzo G; Efstathiou E; Finn SP; Fosså S; Gillessen S; Kellokumpu-Lehtinen PL; Lecouvet FE; Oudard S; de Reijke TM; Robson CN; De Santis M; Seruga B; de Wit R
Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).
Sonpavde G; Wang CG; Galsky MD; Oh WK; Armstrong AJ
BJU Int; 2015 Jul; 116(1):17-29. PubMed ID: 25046451
[TBL] [Abstract][Full Text] [Related]
6. Sequencing current therapies in the treatment of metastatic prostate cancer.
Valenca LB; Sweeney CJ; Pomerantz MM
Cancer Treat Rev; 2015 Apr; 41(4):332-40. PubMed ID: 25784591
[TBL] [Abstract][Full Text] [Related]
7. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
Cereda V; Formica V; Massimiani G; Tosetto L; Roselli M
Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
[TBL] [Abstract][Full Text] [Related]
8. [Treatment sequence using newly developed agents for men with castration resistant prostate cancer].
Fujimoto N
Nihon Rinsho; 2014 Dec; 72(12):2193-7. PubMed ID: 25518357
[TBL] [Abstract][Full Text] [Related]
9. [Options of Chemotherapy in the Treatment of Prostate Cancer].
Richter I; Dvořák J; Bartoš J
Klin Onkol; 2017; 30(1):28-33. PubMed ID: 28185462
[TBL] [Abstract][Full Text] [Related]
10. Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management.
Rozet F; Roumeguère T; Spahn M; Beyersdorff D; Hammerer P
World J Urol; 2016 Nov; 34(11):1505-1513. PubMed ID: 26988552
[TBL] [Abstract][Full Text] [Related]
11. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
[TBL] [Abstract][Full Text] [Related]
12. Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity.
Schutz FA; Buzaid AC; Sartor O
Crit Rev Oncol Hematol; 2014 Sep; 91(3):248-56. PubMed ID: 24613528
[TBL] [Abstract][Full Text] [Related]
13. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
[TBL] [Abstract][Full Text] [Related]
14. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
[TBL] [Abstract][Full Text] [Related]
15. Sequential treatment with taxanes and novel anti-androgenic compounds in castration-resistant prostate cancer.
Esch L; Schulz WA; Albers P
Oncol Res Treat; 2014; 37(9):492-8. PubMed ID: 25231690
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-based treatment for castration-resistant prostate cancer.
Seruga B; Tannock IF
J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
[TBL] [Abstract][Full Text] [Related]
17. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
[TBL] [Abstract][Full Text] [Related]
18. The androgen receptor remains a key player in metastatic hormone-refractory prostate cancer. Implications for new treatments.
Nemes A; Tomuleasa C; Kacso G
J BUON; 2014; 19(2):357-64. PubMed ID: 24965392
[TBL] [Abstract][Full Text] [Related]
19. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
20. Metastatic castrate-resistant prostate cancer: dawn of a new age of management.
Masson S; Bahl A
BJU Int; 2012 Oct; 110(8):1110-4. PubMed ID: 22564337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
